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Abstract
IMPORTANCE—Conclusive intraoperative pathologic confirmation of diffuse infiltrative glioma 
guides the decision to pursue definitive neurosurgical resection. Establishing the intraoperative 
diagnosis by histologic analysis can be difficult in low-cellularity infiltrative gliomas. Therefore, 
we developed a rapid and sensitive genotyping assay to detect somatic single-nucleotide variants 
in the telomerase reverse transcriptase (TERT) promoter and isocitrate dehydrogenase 1 (IDH1).
OBSERVATIONS—This assay was applied to tissue samples from 190 patients with diffuse 
gliomas, including archived fixed and frozen specimens and tissue obtained intraoperatively. 
Results demonstrated 96% sensitivity (95% CI, 90%–99%) and 100% specificity (95% CI, 95%–
100%) for World Health Organization grades II and III gliomas. In a series of live cases, glioma-
defining mutations could be identified within 60 minutes, which could facilitate the diagnosis in an 
intraoperative timeframe.
CONCLUSIONS AND RELEVANCE—The genotyping method described herein can establish 
the diagnosis of low-cellularity tumors like glioma and could be adapted to the point-of-care 
diagnosis of other lesions that are similarly defined by highly recurrent somatic mutations.
World Health Organization (WHO) grade II diffuse gliomas are a group of slow-growing 
primary central nervous system tumors1 for which progression-free and overall patient 
survival correlate with maximal up-front resection.2,3 As a consequence of tumor location, 
infiltrative growth, low cellularity, and often small stereotactic biopsy specimens, 
intraoperative histologic confirmation of diffuse glioma can be challenging.4 This diagnostic 
dilemma often involves multiple surgical samplings or clarification by final pathologic 
analysis several days after the diagnostic biopsy, requiring some patients to undergo a 
second neurosurgical procedure to achieve therapeutic resection. The ability to confirm a 
lesion as glioma during surgery could therefore facilitate intraoperative neurosurgical 
decisions with the potential to decrease risk from additional biopsy samplings or staged 
resections. We therefore developed a platform to simultaneously genotype the highly 
recurrent variants in IDH1 and the TERT promoter, which characterize over 80% of 
gliomas,5 within 60 minutes of tissue acquisition.
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Case records were reviewed, and glioma specimens were obtained under approval of the 
institutional review boards at Dana-Farber Cancer Institute and Massachusetts General 
Hospital. Samples were collected following informed, written consent. The records were 
reviewed under a protocol that allowed analysis of anonymized patient data collected 
following informed, written consent. There was no sex preference when obtaining 
specimens. For specimens with available sex information, the cohort was made up of 49% 
male and 51% female patients.
Rapid Genotyping Assay
We designed a quantitative polymerase chain reaction (PCR)-based method to detect cancer-
specific mutations in specimens with low tumor density through (1) the inclusion of peptide 
nucleic acid (PNA) oligonucleotides that block amplification of wild-type alleles and (2) the 
incorporation of locked nucleic acid (LNA) into the detection probes to increase specific 
binding to the mutant allele (eMethods and eFigures 1 and 2 in the Supplement).
Specifically, this assay was designed to detect IDH1 R132H/C/G/L/S and TERT promoter 
mutations on chromosome 5 at positions 1 295 228 and 1 295 250 based on human genome 
reference version 19, referred to as TERT C228T or TERT C250T (eTable 1 in the 
Supplement). We could detect serial dilutions representing 0.1% to 10.0% of positive control 
genomic extracts diluted in negative control extracts, allowing for estimation of tumor purity 
(eFigures 3 and 4 in the Supplement).
Statistical Analysis
A 2-tailed, nonpaired t test was used to calculate the significance of the difference between 
the number of biopsy attempts required of diagnostic and nondiagnostic cases, with the 
estimated half-width of the 95% CI calculated using a t test distribution in Microsoft Excel. 
The 95% CIs for the reported sensitivity and specificity of the assay were calculated using 
the binomial test in the R statistical package (version 0.98.1091).
Results
To evaluate how intraoperative histologic analysis of low-cellularity tumors affects surgical 
decision making, we reviewed 72 cases of newly diagnosed WHO grade II diffuse gliomas 
treated at Brigham and Women’s Hospital from 2009 through 2014. In this series, biopsy 
specimens obtained in 28 (39%) of 72 cases could not be conclusively diagnosed as glioma 
on the intraoperative frozen specimen (eFigure 5 in the Supplement). These inconclusive 
stereotactic biopsies required additional surgical sampling compared with cases with 
diagnostic biopsies (mean [SD] number of biopsies for conclusive glioma diagnosis, 3.08 
[1.20] vs 1.13 [0.30]; P = .01) (eTable 3 in the Supplement). Because of the anticipated 
difficulty in establishing an intraoperative glioma diagnosis, surgeons may elect to perform a 
stereotactic biopsy before proceeding with a definitive resection in a separate procedure 
following final histologic confirmation.
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To augment intraoperative diagnosis, we developed an assay, OperaGen (for “operative 
genotyping”) to simultaneously genotype IDH1 and TERT promoter variants. We first 
evaluated OperaGen across a range of clinically annotated gliomas by comparing its 
molecular characterization with the histologic diagnosis of 80 archived formalin-fixed, 
paraffin-embedded glioma samples. OperaGen was able to detect every tumor with an IDH1 
R132H mutation (58 of 58 samples, Figure 1A). Concurrent IDH1 and TERT promoter 
mutations detected by OperaGen accurately identified oligodendrogliomas in 38 (95%) of 40 
cases with known 1p/19q codeletion.5 In addition, isolated TERT promoter mutations were 
detected in 17 (77%) of 22 glioblastomas (GBMs), a frequency consistent with prior 
reports.6 The TERT promoter status was confirmed by next-generation sequencing (NGS) 
with coverage greater than 180 000× (eFigure 6 in the Supplement). In addition, patient 
survival correlated with a retrospective analysis of IDH1 and TERT promoter genotype 
status by OperaGen (eFigure 7 in the Supplement).
We next evaluated OperaGen in a cohort of frozen WHO grade II diffuse gliomas to 
determine whether this assay could clarify intraoperative diagnosis in these lower-cellularity 
tumors. Because of the high frequency of IDH1 mutations in these glioma subtypes, we 
designed VIC-conjugated oligonucleotide detection probes to capture additional IDH1 
mutations otherwise not detected by immunohistochemical analysis found in up to 12% of 
IDH1-mutated gliomas.7 When multiplexed with the fluorescein-conjugated IDH1 R132H 
probe, these reactions allowed for simultaneous detection of glioma-specific IDH1 variants, 
discriminating the less frequent mutations from IDH1 R132H (eFigure 8 in the Supplement). 
With this design we were able to detect either IDH1 or TERT promoter mutations in 42 
(95%) of 44 frozen diffuse glioma specimens (Figure 1B).
To explore the possible false-positive rate associated with OperaGen, we analyzed 50 frozen 
GBM specimens (eFigure 9 in the Supplement) and validated the results by high-depth 
sequencing. Separately, 14 non-glioma brain biopsy specimens tested negative for IDH1 and 
TERT promoter variants by OperaGen (eTable 2 in the Supplement). Both specificity and 
sensitivity of diagnosis were high for oligodendrogliomas, diffuse astrocytomas, 
oligoastrocytomas, and IDH1-mutant GBMs, where the strong relationship to IDH1 
mutation in this aggregated series of 174 cases revealed 96% sensitivity (95% CI, 90%–
99%) and 100% specificity (95% CI, 95%–100%) (eFigure 9 in the Supplement). In 
contrast, sensitivity was lower for the diagnosis of GBM with isolated TERT promoter 
mutations, consistent with reported rates in this tumor type and likely a reflection of 
alternative mechanisms of telomere maintenance.8
We observed a higher rate of inconclusive intraoperative histology with stereotactic biopsies 
compared with resections (62% vs 23%, Figure 2A). Because of its sensitivity, we asked 
whether OperaGen could identify glioma-specific mutations in limited tissue obtained from 
stereotactic biopsies. We identified 14 cases of glioma for which intraoperative pathology 
was inconclusive in spite of repeated biopsy sampling (eTable 3 in the Supplement). In 93% 
of these cases (13 of 14), we were able to identify TERT promoter or IDH1 variants in the 
first available specimen (first or second biopsy core, Figure 2B). As illustrated by these 
results, OperaGen could help establish a glioma diagnosis while minimizing the number of 
biopsies and the risks associated with additional passes.9
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We next demonstrated that this assay could be carried out during glioma resection, ruling out 
the presence of 0.1% mutant allele fraction within 60 minutes (eFigures 3 and 10 in the 
Supplement). We present 2 cases to demonstrate how this workflow could be applied in a 
clinical setting. The first case illustrates the ability to detect TERT C228T in GBM (Figure 
3A). The second patient had a frozen section diagnosis of GBM; however, OperaGen 
detected an IDH1 R132H mutation and no TERT promoter mutation, which raised the 
possibility of a WHO grade II or III glioma (Figure 3B). Indeed, the pathologic assessment 
from the permanent specimen ultimately established the tumor as an IDH1-mutant WHO 
grade III anaplastic oligoastrocytoma. While intraoperative histologic analysis confirmed the 
lesion as glioma, further molecular classification as an IDH1-mutant tumor could guide the 
decision to extend the surgical margin into adjacent nonenhancing tumor.2,3
Discussion
Histologic assessment combined with molecular testing can provide a more accurate 
integrated diagnosis of brain tumors.10 In accord, research techniques have applied real-time 
PCR detection of IDH1 mutation11 or mass spectrometry to the intraoperative detection of 2-
hydroxyglutarate, the metabolite of mutant IDH1.12 OperaGen was designed to 
simultaneously detect distinguishing genomic features in both the TERT promoter and IDH1 
to sensitively identify diffuse glioma in an intraoperative timeframe. Optimal surgical 
intervention is shaped by the glioma subtype, since unlike primary GBM, IDH1-mutant 
gliomas appear to benefit from complete resection of enhancing and nonenhancing 
disease.2,3
While alternative techniques such as NGS can also detect somatic variants in low-purity 
tumors, the equipment, time, and analytical methods required for NGS preclude widespread 
clinical use and intraoperative application. Herein we have demonstrated an approach that 
can identify tumor-specific alterations to a sensitivity of 0.1% mutant allele fraction within 
60 minutes. We envision running this assay in parallel with frozen section analysis to 
augment cases where pathologic findings may be inconclusive. Though this testing may add 
time to these inconclusive cases, a definitive molecular diagnosis could reduce the instances 
of repeated biopsies, as highlighted in Figure 2, limiting the potential hazards associated 
with multiple sampling. Furthermore, the availability of intraoperative molecular 
information could obviate the need for staged craniotomies, thus reducing the risks 
associated with a second neurosurgical procedure. Before provisioning Opera-Gen for 
clinical use, larger cohort studies will be needed to address false-positive and false-negative 
rates resulting from issues related to tissue quality or surgical sampling error. The ability to 
obtain intraoperative molecular information also expands the possibility of administering 
direct intratumoral therapy or performing interstitial thermal ablation of glioma in a single 
procedure.13
Conclusions
The molecular genotyping approach described herein has potential application beyond the 
diagnosis of diffuse gliomas. TERT promoter mutations have been identified in a large 
number of other cancers5 and appear to distinguish tumor from non-neoplastic tissue. The 
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principles of this assay could also be applied to other conditions associated with well-
defined variants, such as KRAS, BRAF, and EGFR mutants to facilitate precise 
intraoperative marginal analysis.14,15 Ultimately, such translational genomic approaches are 
critical for improving point-of-care diagnosis in the era of precision cancer medicine.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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• Intraoperative diagnosis of diffuse glioma is critical for distinguishing tumor 
from nonneoplastic mimics and defining the goals of neurosurgical resection.
• Intraoperative genotyping for recurrent mutations in IDH1 and the TERT 
promoter could characterize over 80% of diffuse gliomas.
• This assay was validated on 174 glioma specimens and was able to correctly 
identify WHO grades II and III glioma with 96% sensitivity (95%CI, 90%–
99%) and 100% specificity (95%CI, 95%–100%).
• Glioma-defining mutations were identified in 13 of 14 previously inconclusive 
intraoperative stereotactic biopsy samples.
• It is possible to characterize glioma-defining mutations within 60 minutes 
during a live neurosurgical resection.
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Figure 1. Operative Genotyping (OperaGen) for Molecular Characterization of Glioma
A, The top row of segmented colored bars represents detection of mutations in IDH1 and 
TERT by OperaGen in 80 archived glioma cases (1 case for each bar segment), with variants 
not detected (ND) in 5 specimens (gray segments). The second row represents final 
conventional neuropathologic diagnosis of each case, demonstrating concordance with 
OperaGen. The third row represents the clinical assessment of chromosome 1p/19p deletion 
by FISH or array CGH and is represented in black if the test result was positive and brown if 
it was untested. The bottom row illustrates that intraoperative frozen section analysis was 
diagnostic (purple) in 22 of 22 GBMs but inconclusive (pink) in 10 of 58 WHO grade II and 
III gliomas. B, Validation of OperaGen on archived frozen WHO grade II 
oligodendrogliomas, oligoastrocytomas, and astrocytomas revealed presence of IDH1 or 
TERT promoter mutations in 42 of 44 specimens. Five samples were noted to have 
noncanonical IDH1 mutations by specific VIC-conjugated oligonucleotide probes. Results 
were validated by targeted high-depth sequencing of these genes. CGH Indicates array 
comparative genomic hybridization; FFPE, formalin-fixed, paraffin-embedded; FISH, 
fluorescence in situ hybridization; GBM, glioblastoma; NGS, next-generation sequencing; 
WHO, World Health Organization.
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Figure 2. Molecular Characterization of Stereotactic Biopsy Specimens Facilitates the Diagnosis 
of Glioma
A, Analysis of WHO grade II gliomas newly diagnosed by stereotactic biopsy revealed that 
18 of 29 cases had inconclusive intraoperative histologic findings (each radial circle segment 
represents 1 case). B, Tissue from 14 glioma cases with inconclusive intraoperative 
histologic findings were assessed by OperaGen. The total number of biopsy specimens 
obtained for each case is listed in the top row, while the first available stereotactic biopsy 
specimen used for OperaGen testing is listed in the second row. OperaGen detected either an 
IDH1 mutation (third row) or TERT promoter mutation (fourth row) in 13 of 14 cases. Final 
histologic diagnosis and WHO grade obtained by conventional neuropathologic analysis are 
listed in bottom 2 rows. GBM, glioblastoma; WHO, World Health Organization.
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Figure 3. Sensitive Detection of Glioma-Specific Somatic Variants Within an Intraoperative 
Timeframe Using Operative Genotyping (OperaGen)
A, Case 1 demonstrates the detection of TERT promoter mutation from a specimen that was 
diagnosed as high-grade glioma on intraoperative frozen specimen analysis (single 
arrowhead indicating microvascular proliferation; double arrowhead, necrosis) and GBM on 
permanent specimen analysis (single arrowhead indicating microvascular proliferation). 
Both specimens stained with hematoxylin-eosin. B, Case 2 frozen specimen (hematoxylin-
eosin) was diagnosed as GBM based on the presence of microvascular proliferation (single 
black arrowhead) and mitotic figures (single green arrowhead). The OperaGen detection of 
IDH1 R132H would alternatively have been consistent with WHO grade II or III glioma, 
which was in agreement with findings of the permanent specimen analysis of IDH1-mutant 
anaplastic oligoastrocytoma (immunohistochemically stained). All scale bars represent 10 
μm. GBM indicates glioblastoma; WHO, World Health Organization.
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